Oprelvekin

Proper name: Oprelvekin
Tradename: Neumega
Manufacturer: Genetics Institute, Inc, Andover, MA, License #1163
Indication for Use: Prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia
Approval Date: 11/25/97
Type of submission: Biologics license application

Approval Letter - (PDF), (Text)

Reviews - (PDF)
    Clinical (54 pages)
    Clinical pharmacokinetic (17 pages)
    CMC 1 (4 pages)
    CMC 2 (3 pages)
    Pharmacology (56 pages)
    Statistical (33 pages)

Talk Paper

Last Updated: 3/5/2001

Back to Top     Back to Index

Updated: September 25, 2003

CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER
FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | HHS Home Page

FDA/Center for Drug Evaluation and Research